Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UNIVACFLU

Financiado

Cerrado

Universal Flu Vaccine

Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antige... ver más

28/02/2018

UGOT - GOETEBORGS...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

GOETEBORGS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

UGOT - GOETEBORGS UNIVERSITE...

0.00€ | Lider

ISTITUTO EUROPEO DI ONCOLOGI...

N.D. | Participante

UDSL

N.D. | Participante

RAILENIUM

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAMUFLU Self amplifying RNA technology applied to the development of... 187K€ Cerrado

INCENTIVE Indo European Consortium for Next Generation Influenza Vacci... 20M€ Cerrado

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

FLUniversal Intranasal, rapid-acting vaccine for all seasonal and pandem... 8M€ Cerrado

UNIFLUVAC A novel universal influenza vaccine targeting epitopes of li... 149K€ Cerrado

AGL2010-22200-C02-02 CARACTERIZACION DE LA RESPUESTA INMUNE INDUCIDA POR CEPAS DE... 157K€ Cerrado

Líder del proyecto

GOETEBORGS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines. The aim is to establish a European training platform to integrate young researchers in a highly innovative interdisciplinary strategy to develop mucosal flu-vaccines. The Universal Influenza Vaccine (UNIFLUVAC) network is aimed at harnessing the expertise of the most accomplished vaccine researchers, developers and regulators in Europe in a timely and multidisciplinary training approach unparalleled in any single EU country. The training program is extensive and builds on the integrated added values of complementing expertise and the full access to state-of-the- art technologies and excellent training environments. This unique consortium has 2 SMEs as fully committed members to guarantee strong intersectoral cooperation between industry and academia. The partners represent 6 leading universities in 6 different member countries, securing excellent presence in Europe. The structure of UNIFLUVAC is specifically adapted to operate over the whole range of specialized expertise needed. Specifically, UNIFLUVAC provides vaccine antigen identification and expression, adjuvant design and formulation, testing in state-of-the-art preclinical animal models and finally clinical safety, immunogenicity and efficacy trials in excellent and for Europe unique medical centres. This is the strength and appeal of the UNIFLUVAC proposal. It will also establish a long-term European network based on a new cohort of young professionals with excellent employability and career opportunities in academic, clinical or industrial settings. UNIFLUVAC will have a major impact on human health in Europe and globally.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores